HealthDay News — An individualized approach to glycemic control in type 2 diabetes is likely to reduce costs and improve quality of life, according to a study published online in the Annals of Internal Medicine.
Neda Laiteerapong, MD, from the University of Chicago, and colleagues estimated the cost-effectiveness of individualized versus uniform intensive control for the US population with type 2 diabetes. Data were obtained from the National Health and Nutrition Examination Survey 2011 to 2012.
The researchers found that, compared with uniform intensive control, individualized control saved $13,547 per patient ($105,307 versus $118,854), mainly due to reduced medication costs ($34,521 versus $48,763). Decreased life expectancy was seen with individualized control (20.63 versus 20.73 years) due to an increase in complications; however, there was an increase in quality-adjusted life-years (QALYs: 16.68 versus 16.58) resulting from fewer hypoglycemic events and fewer medications.
In sensitivity analyses, individualized control was found to be cost-saving and generated more QALYs vsintensive control, except in analysis in which there was at least a 60% reduction in disutility associated with receiving diabetes medication.
“Health policies and clinical programs that encourage an individualized approach to glycemic control for US adults with type 2 diabetes reduce costs and increase quality of life compared with uniform intensive control,” the authors write.
Laiteerapong N, Cooper JM, Skandari MR, et al. Individualized glycemic control for US adults with type 2 diabetes: a cost-effectiveness analysis [published online December 12, 2017]. Ann Intern Med. doi: 10.7326/M17-0537